Skip to main content

New story in Health from Time: ‘We Will Share Our Vaccine with the World.’ Inside the Chinese Biotech Firm Leading the Fight Against COVID-19



It was the Chinese philosopher Sun Tzu, and not Al Pacino in The Godfather Part 2, who first said, “Keep your friends close, and your enemies closer.” Yin Weidong, the CEO of Chinese biotech firm SinoVac, seems to have taken that advice to heart.

On the desk in his office in Beijing are two plastic models of a virus—each blue core surrounded by red protein spikes. From the time it started spreading in the central Chinese city of Wuhan in late December, containing that virus has occupied virtually every waking moment for the scientist.

The pandemic we now know as COVID-19 is rampaging across every continent. On the dozens of daily infection charts, broken down by nation and pasted floor to ceiling on Yin’s office wall, the numbers tell a horrifying story: 16 million infections and 640,000 deaths worldwide, including 146,000 American lives lost as of Monday.

But if the enemy is close, so is a possible new friend. Yin’s desk is now also home to several small glass vials of SinoVac’s COVID-19 vaccine—dubbed CoronaVac—that began phase 3 trials involving 9,000 volunteers in Brazil last week. (A phase 1 trial involves small groups of patients to check a vaccine for negative side effects, and a phase two trial usually tests for a combination of safety and efficacy, while a phase 3 trial is like a phase 2 but involving many more participants.)

“Looking at the data collected, I think we have more than an 80% chance of success,” says Yin.

Normally, getting from pathogen identification through phase 3 trials in about 10 years is considered quick. The mumps vaccine is generally considered the fastest ever developed at four years. But if all goes well, CoronaVac might be ready for regulatory approval early next year. Not that Yin is satisfied.

“Do you really think this is fast? Compared with the spread of the virus, it’s not fast enough,” he says, holding his plastic nemesis aloft with grudging respect. “That is how we should measure our progress.”

During the 2002 to 2003 SARS outbreak, which claimed over 774 lives worldwide, SinoVac was the only firm to go into phase 1 vaccine trials, but the pandemic suddenly disappeared. That meant that research was discontinued at a huge loss for the firm. It wasn’t entirely wasted, however. Now, 17 years later, SinoVac is able to build on that earlier work, given that COVID-19 is very similar to SARS. It and coronavirus are “like brothers,” says Yin.

Still, creating an effective vaccine is just a third of the battle. The other two prongs of vaccine development are production capacity and getting regulatory approval. At present, every nation’s FDA equivalent would need to approve CoronaVac independently, though given the unprecedented need, there are conversations about streamlining.

“The virus doesn’t require a passport but the vaccine needs to be licensed by every country,” says Yin.

SinoVac CEO Yin Weidong
Charlie CampbellSinoVac CEO Yin Weidong in his Beijing office on Tuesday, July 21, 2020.

SinoVac is aiming to triple current capacity to produce 300 million doses per year. That might sound impressive, but accessibility is likely to be a big issue. Given that at least two doses will be required to immunize one person, it would still take almost a decade to vaccinate every person in China alone, never mind sharing the vaccine with the world’s 7.6 billion people.

“If only one or two countries get protected this won’t solve the problem and get economic activity back to normal” Yin says.

SinoVac isn’t the only company with a potential vaccine in clinical evaluation. There are over 20 companies around the world engaged in the task with more than 130 vaccines in development, according to the WHO. But given the scale of the need, there’s going to be no quick fix to the pandemic.

Another vaccine candidate, developed by U.S. biotech firm Moderna with the National Institutes of Health, provoked the desired immune response in a test of 45 individuals, and is about to enter phase 3 trials. It functions by introducing an mRNA sequence—a molecule that tells cells what to build—coded for a disease-specific antigen. Once produced within the body, the antigen is logged by the immune system, empowering it to fight the real virus.

But while such RNA vaccines, as they’re known, have multiple benefits—including speed of production—they must be stored at sub-zero temperatures. That means their distribution to far-flung populations is problematic. While SinoVac initially experimented with RNA and other vaccine prototypes, they found that a traditional inactivated virus vaccine produced the best results. Under normal conditions, Yin believes CoronaVac has a shelf life of three years.

“The purpose of this work is not to discover which technology is better,” says Yin. “The purpose is to control the disease.”

In principle, SinoVac is a private company that owns CoronaVac as its licensed intellectual property, meaning where the vaccine is distributed should be a purely commercial decision. However, the Chinese government has contributed to the estimated one billion renminbi (about $140 million) the firm is investing in CoronaVac. This and other contributions from international NGOs currently under negotiation all come with distribution commitments attached.

In a speech to the World Health Assembly on May 18, Chinese President Xi Jinping promised to make a COVID-19 vaccine produced in China a “global public good.” In reality, of course, every queue has someone at the back, meaning there will be much jostling for priority—and potentially boosting Beijing’s global clout.

According to Benjamin N. Gedan, a former regional director on the White House’s National Security Council now with the Wilson Center, “If China produces the first coronavirus vaccine at scale, it would be an extraordinary diplomatic tool anywhere in the world.”

SinoVac has already committed to sharing 60-100 million doses in Brazil through a collaboration with São Paulo-based Instituto Butantan, which is performing the phase 3 study. In Asia, the firm is “actively in discussion with several countries,” says Yin, including Indonesia and Turkey, and is exploring options in Europe. It has also had more than 30 meetings with the WHO to update the global health body on its progress.

“We will share our vaccine with the world,” says Yin.

Popular posts from this blog

New story in Health from Time: 3 More People Diagnosed With Coronavirus in Northern California

Three more people in Northern California have been diagnosed with the coronavirus known as 2019-nCoV, health officials in the area said Sunday, doubling the number of cases in the state and bringing the total across the country to 11 . The patients, whose symptoms are not yet serious enough to warrant hospitalization, are being kept in their homes, where they are being closely monitored, the San Francisco Chronicle reports . Two of the patients are a husband and wife from San Benito County. The husband fell ill after he returned home from Wuhan, China, where the outbreak began. It is believed he transferred the virus to his wife, who had not been to China. The other patient became sick while visiting family in Santa Clara County. She also previously visited Wuhan. Since arriving in the United States on Jan. 23, she has only left her home twice to seek out medical assistance. Officials from both counties said they are working to identify anyone who may have come into cont...

New video by blogilates on YouTube

Day 8 - 14 | Blogilates 2020 Challenge You guys are CRUSHING the #2020Challenge so far! Idk about you but my abs are soooooore! This week, we're doing 20 reps of abs every day + 20 reps of another new exercise every day! If you need a little extra motivation, text my number (510-692-4556) and tell me all about it so we can come up with a solution together! This link also works: https://ift.tt/2Qjqw7G This week's moves are: Jan. 8th (starts 0:48) - 20 butterfly bridges + 20 criss cross (butt + abs) Jan. 9th (starts 2:43) - 20 oil riggers + 20 rollovers (arms + abs) Jan. 10th (starts 8:29) - 20 lunges + 20 leg outs (legs + abs) Jan. 11th (starts 11:03) - 20 walnut crushers + 20 single leg drops (back + abs) Jan. 12th (starts 13:41) - 20 sprinters + 20 crunches (obliques + abs) Jan. 13th (starts 16:27) - 20 squat jumps + 20 russian twists (cardio + abs) Jan. 14th (starts 18:57) - 20 plank jacks + 20 butt ups (total body + abs) Here is where I get all of my music! Epidemic Sound: ...

New story in Health from Time: Coronavirus Cases Outside China Are Accelerating Rapidly. Here’s What to Know

A surge in deadly coronavirus cases outside China is raising concerns that the outbreak has reached a new stage and could continue its global spread to even more vulnerable countries. In the central Chinese province of Hubei, where the virus is believed to have originated, the number of cases appears to be stabilizing, according to government figures. But the number of people infected elsewhere in the world is rising quickly, with clusters in South Korea , Italy, Iran and a cruise ship docked in Japan. As of Monday, more than 2,200 cases of the virus, officially called COVID-19, have been reported outside of mainland China, where the overwhelming majority of the 79,000 cases have been located since officials first discovered the disease in December. The number of deaths outside China has also increased to 166, including 50 in Iran and four in Italy. In a news conference Monday, World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus said the WHO...